CoChat

Glucagon-Like Peptide-1 (GLP-1)-Based Therapeutics: Current Status and Future Opportunities beyond Type 2 Diabetes

Cheang, Jia Ying, Moyle, Peter M. · 2018 · ChemMedChem

The DOI matches its Crossref record; 73 of the 73 references it cites were found in a registry or an index.

Abstract

Glucagon‐like peptide‐1 (GLP‐1) is secreted by intestinal L‐cells following food intake, and plays an important role in glucose homeostasis due to its stimulation of glucose‐dependent insulin secretion. Further, GLP‐1 is also associated with protective effects on pancreatic β‐cells and the cardiovascular system, decreased appetite, and weight loss, making GLP‐1 derivatives an exciting treatment for type 2 diabetes and obesity. Despite these benefits, wild‐type GLP‐1 exhibits a short circulation time due to its poor metabolic stability and rapid renal clearance, and must be administered by injection, making it a poor therapeutic agent. Many strategies have been used to improve the circulation time of GLP‐1 (e.g., mutations, unnatural amino acids, depot formulations, use of exendin‐4 sequences, and fusions with high‐molecular‐weight proteins or polymers), with its therapeutic utility further improved by adding agonist activity for gastric inhibitory peptide and glucagon receptors. This minireview focuses on strategies that have been used to improve the pharmacokinetics of GLP‐1 and provides an overview of GLP‐1‐based therapeutics in the pipeline.

Overview

Integrity signals

Registry

Crossref · 10.1002/cmdc.201700781

Cites

73 of 73 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Verification

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Citations

Cites

Show all 73 references

Research works printed but not linked: 9

  1. Krause A., 2010, Formulary, 45, 43
  2. Jackson S. H., 2010, Pharmacy Ther., 35, 498
  3. Willard F. S., 2012, Exp. Diabetes Res., 470851
  4. Woodward H. N., 2014, Patient Preference Adherence, 8, 789
  5. Pratley R. E., 2014, Diabetes Endocrinol., 2, 289
  6. Spiegelberg H., 1972, Clin. Exp. Immunol., 10, 599
  7. Jimenez-Solem E., 2010, Curr. Opin. Mol. Ther., 12, 790
  8. Davies M. L., 2016, Austin J. Endocrinol. Diabetes, 3, 1053
  9. 10.1021/bc049735 · doi:10.1021/bc049735

Cited by

See all 84

Metadata

Authors
Cheang, J. Y., & Moyle, P. M.
Affiliations
The University of Queensland (AU)
Corresponding author
Moyle, Peter M.
Venue
ChemMedChem
Publisher
Wiley
Published
2018-02-28
Volume
13
Issue
7
Pages
662-671
ISSN
  • 1860-7179 (ISSN-L)
  • 1860-7187
OpenAlex
W2792698729
Cited by
82
References
73
Citations by year
2026: 3 · 2025: 5 · 2024: 16 · 2023: 9 · 2022: 9 · 2021: 14 · 2020: 13 · 2019: 11 · 2018: 2
FWCI
1.58
Type
journal article
Language
en
Open access
closed
Locations
  • ChemMedChem (publishedVersion)
  • PubMed (publishedVersion)
Funders
University of Queensland
Topics
  • Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
  • Physical Sciences › Chemistry › Organic Chemistry › Chemical Synthesis and Analysis
  • Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Pancreatic function and diabetes
Keywords
glucagon-like peptide-1, GLP-1 receptor agonists, type 2 diabetes, obesity, pharmacokinetics, GLP-1 analogues, exendin-4, glucose-dependent insulinotropic polypeptide, glucagon receptor, pancreatic beta-cell protection, glucose homeostasis, insulin secretion
MeSH terms
Liraglutide, Exenatide, Animals, Delayed-Action Preparations, Diabetes Mellitus, Type 2, Half-Life, Humans, Hypoglycemic Agents, Structure-Activity Relationship, Peptide Hormones, Glucagon-Like Peptide 1

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.